Market Place
Sourcing Support
XORTX Study Presented At ASN Kidney Week 2024
24 Oct 2024 //
GLOBENEWSWIRE
XORTX Closes US$1.5 Million Registered Direct Offering
18 Oct 2024 //
GLOBENEWSWIRE
XORTX Prices $1.5 Million Direct Offering And Placement
17 Oct 2024 //
GLOBENEWSWIRE
XORTX Initiates Precision Medicine Program
09 Oct 2024 //
GLOBENEWSWIRE
XORTX Announces Results of Annual and Special Meeting of Shareholders
13 Sep 2024 //
GLOBENEWSWIRE
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
12 Sep 2024 //
GLOBENEWSWIRE
XORTX Reminds Shareholders Of Voting Deadline For Annual Meeting
06 Sep 2024 //
GLOBENEWSWIRE
ISS Recommends XORTX Shareholders Vote FOR All Annual Meeting Proposals
03 Sep 2024 //
GLOBENEWSWIRE
XORTX Highlights Research on Genetic Regulation of Xanthine Oxidase Targeting
29 Aug 2024 //
GLOBENEWSWIRE
XORTX Announces Filing Of Meeting Documents For Annual And Special Meeting
23 Aug 2024 //
GLOBENEWSWIRE
XORTX To Present At American Society Of Nephrology Kidney Week 2024
20 Aug 2024 //
GLOBENEWSWIRE
XORTX to Present at BIO International Convention 2024
04 Jun 2024 //
GLOBENEWSWIRE
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
17 May 2024 //
GLOBENEWSWIRE
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
30 Apr 2024 //
GLOBENEWSWIRE
XORTX Announces Publication of Key Research in ADPKD
22 Apr 2024 //
GLOBENEWSWIRE
XORTX Announces Participation in Spring 2024 Investor Conferences
08 Apr 2024 //
GLOBENEWSWIRE
XORTX Welcomes New Member to the Board of Directors
08 Apr 2024 //
GLOBENEWSWIRE
XORTX Announces New Clinical Advisory Board Member
27 Mar 2024 //
GLOBENEWSWIRE
XORTX Highlights Achievements of 2023 & Preparation for Registration Trial
19 Mar 2024 //
GLOBENEWSWIRE
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
11 Mar 2024 //
GLOBENEWSWIRE
XORTX Finalizes $2.7M Prospectus Supplement and Concurrent Private Placement
04 Mar 2024 //
GLOBENEWSWIRE
XORTX Raises $2.5 Million Under Prospectus Supplement
15 Feb 2024 //
GLOBENEWSWIRE
XORTX Restated Prospectus Supplement for the Offering of Units
01 Feb 2024 //
GLOBENEWSWIRE
XORTX Announces $2 Million Public Offering
15 Jan 2024 //
GLOBENEWSWIRE
XORTX Welcomes New Member to the Board of Directors
02 Jan 2024 //
GLOBENEWSWIRE
XORTX Announces US ATM Offering
30 Nov 2023 //
GLOBENEWSWIRE
XORTX Meets Nasdaq Continued Listing Requirements
29 Nov 2023 //
GLOBENEWSWIRE
XORTX Clarifies Timing for Share Consolidation
10 Nov 2023 //
GLOBENEWSWIRE
XORTX Announces Share Consolidation
08 Nov 2023 //
GLOBENEWSWIRE
XORTX Study Presented at the American Society of Nephrology “ Kidney Week 2023
02 Nov 2023 //
GLOBENEWSWIRE
XORTX Announces Results of Special Meeting of Shareholders
27 Oct 2023 //
GLOBENEWSWIRE
XORTX Announces Rescheduling of Special Meeting of Shareholders
25 Oct 2023 //
GLOBENEWSWIRE
XORTX Announces Date for Rescheduled Special Meeting of Shareholders
25 Oct 2023 //
GLOBENEWSWIRE
ISS, Recommends Shareholders Vote for the Share Consolidation Resolution
12 Oct 2023 //
GLOBENEWSWIRE
XORTX Calls Special Meeting of Shareholders
04 Oct 2023 //
GLOBENEWSWIRE
XORTX Sponsored Study Selected for Presentation
28 Sep 2023 //
GLOBENEWSWIRE
XORTX Announces Participation at Upcoming Investor Conferences
11 Sep 2023 //
GLOBENEWSWIRE
XORTX Joins the Kidney Foundation and Kidney March
07 Sep 2023 //
GLOBENEWSWIRE
XORTX Submits Orphan Drug Desig. to the EMA to Treat Progressive Kidney Disease
29 Aug 2023 //
GLOBENEWSWIRE
XORTX Appoints Chief Financial Officer
04 Aug 2023 //
GLOBENEWSWIRE
XORTX Announces Results of Annual and Special Meeting of Shareholders
29 Jun 2023 //
GLOBENEWSWIRE
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline
23 Jun 2023 //
GLOBENEWSWIRE
XORTX Announces PKD Presentation
06 Jun 2023 //
GLOBENEWSWIRE
XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq
24 May 2023 //
GLOBENEWSWIRE
FDA Confirms Eligibility of XORLO„¢ for Accelerated Approval
04 May 2023 //
GLOBENEWSWIRE
XORTX Announces Receipt of FDA ODD to Treat Autosomal Dominant Kidney Disease
21 Apr 2023 //
GLOBENEWSWIRE
XORTX Announces Type D Meeting with FDA to be held May 1, 2023
14 Mar 2023 //
GLOBENEWSWIRE
XORTX Provides Update on 2022 Achievements and 2023 Planned Milestones
07 Feb 2023 //
GLOBENEWSWIRE
XORTX Announces Submission of Orphan Drug Designation Request for XRx-008
01 Feb 2023 //
GLOBENEWSWIRE
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial
19 Jan 2023 //
GLOBENEWSWIRE
XORTX Files New Provisional Patent to Diagnose & Treat Individuals Most at Risk
03 Jan 2023 //
GLOBENEWSWIRE
XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study
19 Dec 2022 //
GLOBENEWSWIRE
XORTX Announces Enrollment in Bridging Pharmacokinetics Study
28 Nov 2022 //
GLOBENEWSWIRE
XORTX Announces Receipt of Nasdaq Notification Regarding Bid Price Deficiency
25 Nov 2022 //
GLOBENEWSWIRE
XORTX Presents New Proof of Concept Data at American Society of Nephrology
03 Nov 2022 //
GLOBENEWSWIRE
XORTX Receives Further No Objection Letter from Health Canada
26 Oct 2022 //
GLOBENEWSWIRE
XORTX Sponsored American Society of Nephrology Study Abstract Available Online
25 Oct 2022 //
GLOBENEWSWIRE
XORTX Announces Closing of US$5 Million Public Offering
07 Oct 2022 //
GLOBENEWSWIRE
XORTX Announces US$5 Million Public Offering
04 Oct 2022 //
GLOBENEWSWIRE
XORTX Completes Positive Pre-Phase 3 Meeting with the USFDA
19 Sep 2022 //
GLOBENEWSWIRE
